On February 11, 2014, the pan-Canadian Oncology Drug Review (pCODR) invited stakeholder comments on proposed changes to the pCODR Procedures and related guidance documents.A summary of the stakeholder feedback can be found here.
In view of the stakeholder comments, effective June 1, 2014, pCODR will no longer require a letter confirming ability to supply, the drug notification form and the patent expiry information for both pre-NOC and post-NOC submissions to pCODR. However, the pCODR-participating drug plans will contact manufacturers directly if they have needs relating to these submission requirements.
pCODR anticipates the consideration and application of all stakeholder comments to be finalized by Summer 2014. A notice will be issued prior to any applicable changes to the pCODR Documents, so as to reduce the impact of timing on those working on submissions to the process.